Bank of America Raises Johnson & Johnson (NYSE:JNJ) Price Target to $221.00

Johnson & Johnson (NYSE:JNJ) had its price objective lifted by investment analysts at Bank of America from $220.00 to $221.00 in a research note issued to investors on Thursday,Benzinga reports. The brokerage presently has a “neutral” rating on the stock. Bank of America‘s price target indicates a potential upside of 0.69% from the stock’s current price.

Several other equities research analysts also recently commented on the stock. Guggenheim boosted their target price on shares of Johnson & Johnson from $206.00 to $227.00 and gave the stock a “buy” rating in a research report on Friday, December 5th. UBS Group reiterated a “buy” rating on shares of Johnson & Johnson in a research note on Monday, January 5th. Citigroup reissued a “buy” rating on shares of Johnson & Johnson in a research note on Thursday. HSBC restated a “buy” rating and issued a $240.00 target price on shares of Johnson & Johnson in a report on Wednesday, December 10th. Finally, Weiss Ratings reiterated a “buy (b)” rating on shares of Johnson & Johnson in a report on Friday, October 31st. Two analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat.com, Johnson & Johnson currently has an average rating of “Moderate Buy” and an average price target of $219.05.

Johnson & Johnson Trading Up 0.7%

JNJ stock traded up $1.49 during midday trading on Thursday, hitting $219.50. The stock had a trading volume of 6,705,808 shares, compared to its average volume of 9,494,531. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50. The firm has a market cap of $528.83 billion, a P/E ratio of 21.19, a price-to-earnings-growth ratio of 2.24 and a beta of 0.34. The business has a fifty day moving average price of $207.39 and a two-hundred day moving average price of $188.27. Johnson & Johnson has a 1-year low of $141.50 and a 1-year high of $222.17.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, January 21st. The company reported $2.46 earnings per share for the quarter, meeting the consensus estimate of $2.46. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. The company had revenue of $24.56 billion during the quarter, compared to analyst estimates of $24.14 billion. During the same quarter in the previous year, the business posted $2.04 EPS. Johnson & Johnson’s revenue for the quarter was up 9.1% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.430-11.630 EPS. On average, sell-side analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Johnson & Johnson

Several institutional investors have recently added to or reduced their stakes in the business. Abich Financial Wealth Management LLC bought a new position in shares of Johnson & Johnson in the third quarter worth $26,000. Clayton Financial Group LLC purchased a new stake in Johnson & Johnson during the 3rd quarter worth about $28,000. Evolution Wealth Management Inc. bought a new position in Johnson & Johnson in the 2nd quarter worth about $27,000. Stone House Investment Management LLC grew its holdings in Johnson & Johnson by 58.9% during the 4th quarter. Stone House Investment Management LLC now owns 197 shares of the company’s stock valued at $41,000 after buying an additional 73 shares in the last quarter. Finally, Semmax Financial Advisors Inc. grew its holdings in Johnson & Johnson by 55.0% during the 2nd quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock valued at $31,000 after buying an additional 72 shares in the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Q4 results and 2026 guidance beat/raised — JNJ reported solid Q4 revenue and issued FY‑2026 EPS and sales guidance above consensus, highlighting oncology and MedTech growth that underpin near‑term revenue visibility. Johnson & Johnson reports Q4 and Full-Year 2025 results
• Positive Sentiment: Analyst upgrade with meaningful upside — Scotiabank raised its JNJ price target to $265 and gave a “sector outperform” rating, providing a sizable upside case that can attract buy‑side flows. Scotiabank price target raise
• Positive Sentiment: MedTech tailwinds and new product optionality — Management flagged MedTech strength (robotic surgery/OTTAVA submission) and durable oncology sales (e.g., Darzalex), which support durable growth and dividend coverage. MedTech sales and product launches
• Positive Sentiment: Dividend strength and investor confidence — Coverage pieces note JNJ’s status as a Dividend King with a sustainable payout and yield that supports total‑return buying. Why JNJ is a Top Dividend Stock
• Neutral Sentiment: Smaller analyst moves and mixed ratings — Stifel nudged its target to $220 (hold), and consensus remains a moderate buy; incremental target changes are supportive but not uniformly bullish. Stifel target change
• Neutral Sentiment: Street commentary and flow — Positive mentions from high‑profile investors/commentators (e.g., Jim Cramer) and trend‑following buy signals are lifting sentiment, but they can amplify intraday volatility. Jim Cramer on JNJ
• Negative Sentiment: Talc litigation advancing — Courts are allowing plaintiffs’ expert testimony in MDL proceedings, a legal overhang that increases trial risk and potential liability headlines. Talc plaintiffs evidence to be heard
• Negative Sentiment: Stelara biosimilar pressure — Loss of patent protection has driven steep Stelara sales declines, and ongoing biosimilar competition is a structural headwind to Immunology revenue. Stelara biosimilar impact

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.